
Israeli biotech Sol-Gel nets $80.2mm in Nasdaq IPO
Executive Summary
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
-
Drug Delivery
- Controlled Release
- Topical Delivery
Deal Status
- Final
Deal Type
-
Financing
- IPO
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com